A Retrospective Comparison of Taxane and Fluorouracil-based Chemoradiotherapy in Patients with Inoperable Esophageal Squamous Cell Carcinoma.
OBJECTIVE
To retrospectively compare taxane-based with fluorouracil-based chemoradiotherapy in terms of toxicity profiles, efficacy and survival in patients with inoperable esophageal cancer.


METHODS
We analyzed retrospectively 179 consecutive patients who were unresectable or medically unfit for surgery between March 2009 and November 2014. Eight-three patients were included in the taxane group and 96 cases were in the fluorouracil group.


RESULTS
The overall response rate (ORR) in the taxane group was higher than fluorouracil group, but was not significantly different (71.6% vs. 63.5%, respectively, P=0.255). In total, 53.0% (44/83) of the patients in the taxane group had progressive disease versus 54.2% (52/96) in the fluorouracil group (not significantly different (P=0.758)). There was no significant difference in overall response rate, progression free survival and overall survival, as well as treatment-related death. In terms of non-hematological toxicity, patients in the taxane group experienced a lower incidence of ≥ grade 3 esophageal perforation or fistula (4.8% vs. 13.5%, P=0.047) and pneumonia (4.8% vs. 9.7%, P=0.242). Regarding hematological toxicity, thrombocytopenia in the taxane group was significantly lower (4.8% vs. 13.5%, P=0.047), but there was a trend towards a higher rate of ≥ grade 3 leukopenia (34.9% vs.26.0%, P=0.196).


CONCLUSIONS
Chemoradiation with taxane-based regimens is well tolerated, with potentially promising efficacy, and could become a good alternative treatment in a first line setting for patients with inoperable esophageal squamous cell carcinoma.
1. Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou China;
Xiaojiang
X
Sun
1. Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou China;
Shuiyun
S
Han
1. Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou China;
Feiying
F
Gu
1. Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou China;
Gang
G
Lin
1. Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou China;
Zhun
Z
Wang
1. Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou China;
Yuezhen
Y
Wang
1. Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou China;; 2. Key Laboratory of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou 310022, China.
Yaping
Y
Xu
chemoradiotherapy; esophageal cancer; esophageal squamous cell carcinoma; taxane